439 related articles for article (PubMed ID: 25908780)
1. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
Yonezawa A; Dutt S; Chester C; Kim J; Kohrt HE
Clin Cancer Res; 2015 Jul; 21(14):3113-20. PubMed ID: 25908780
[TBL] [Abstract][Full Text] [Related]
2. CD137, an attractive candidate for the immunotherapy of lung cancer.
Ye L; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Cancer Sci; 2020 May; 111(5):1461-1467. PubMed ID: 32073704
[TBL] [Abstract][Full Text] [Related]
3. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
[TBL] [Abstract][Full Text] [Related]
4. An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses.
Hong JP; Reynoso GV; Andhey PS; Swain A; Turner JS; Boon ACM; Krammer F; Ellebedy AH; Zanini F; Artyomov M; Hickman HD; Diamond MS
Cell Rep Med; 2020 Jun; 1(3):. PubMed ID: 32699843
[TBL] [Abstract][Full Text] [Related]
5. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.
Stoll A; Bruns H; Fuchs M; Völkl S; Nimmerjahn F; Kunz M; Peipp M; Mackensen A; Mougiakakos D
Leukemia; 2021 Dec; 35(12):3482-3496. PubMed ID: 34021248
[TBL] [Abstract][Full Text] [Related]
6. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
Eskiocak U; Guzman W; Wolf B; Cummings C; Milling L; Wu HJ; Ophir M; Lambden C; Bakhru P; Gilmore DC; Ottinger S; Liu L; McConaughy WK; He SQ; Wang C; Leung CL; Lajoie J; Carson WF; Zizlsperger N; Schmidt MM; Anderson AC; Bobrowicz P; Schuetz TJ; Tighe R
JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161196
[TBL] [Abstract][Full Text] [Related]
7. The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention.
Luu K; Shao Z; Schwarz H
J Leukoc Biol; 2020 May; 107(5):731-738. PubMed ID: 32052477
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
Houot R; Goldstein MJ; Kohrt HE; Myklebust JH; Alizadeh AA; Lin JT; Irish JM; Torchia JA; Kolstad A; Chen L; Levy R
Blood; 2009 Oct; 114(16):3431-8. PubMed ID: 19641184
[TBL] [Abstract][Full Text] [Related]
9. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
Chester C; Ambulkar S; Kohrt HE
Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
[TBL] [Abstract][Full Text] [Related]
12. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.
Sánchez-Paulete AR; Cueto FJ; Martínez-López M; Labiano S; Morales-Kastresana A; Rodríguez-Ruiz ME; Jure-Kunkel M; Azpilikueta A; Aznar MA; Quetglas JI; Sancho D; Melero I
Cancer Discov; 2016 Jan; 6(1):71-9. PubMed ID: 26493961
[TBL] [Abstract][Full Text] [Related]
13. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
14. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
Yonezawa A; Chester C; Rajasekaran N; Kohrt HE
Chin Clin Oncol; 2016 Feb; 5(1):5. PubMed ID: 26932429
[No Abstract] [Full Text] [Related]
16. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
18. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
19. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
20. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
Kohrt HE; Houot R; Goldstein MJ; Weiskopf K; Alizadeh AA; Brody J; Müller A; Pachynski R; Czerwinski D; Coutre S; Chao MP; Chen L; Tedder TF; Levy R
Blood; 2011 Feb; 117(8):2423-32. PubMed ID: 21193697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]